Abstract
Oxidative stress is considered a possible mechanism in Parkinson’s disease (PD) progression. Bilirubin has been recognized as a powerful antioxidant that increases due to heme-oxygenase activity. We aimed to investigate the association of total bilirubin (TB) with motor signs and asymmetry in different stages of early PD. A case–control study was performed to investigate the differences in TB levels in PD patients and healthy controls (HC) both carrying LRRK2 variants. We compared TB levels in HC and Hoehn and Yahr (HY) I and II cohorts separately, followed by multiple linear regression analysis to evaluate the association between TB and motor dysfunction in each stage. We used Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (UPDRS) part III scores and asymmetry scores to address motor disability. Asymmetry scores were calculated from the corresponding UPDRS III tasks. TB was significantly increased in HY II compared to HC (P < 0.001). Positive correlations with TB were found for UPDRS III total score (ρ = 0.303, P = 0.034) and asymmetry score (ρ = 0.418, P = 0.003) in HY I. Multiple linear regression found a significant relationship between TB and asymmetry scores in HY I (R2 = 0.261, P = 0.037), but no relationship was achieved with UPDRS III total scores. Increased TB serves as an important diagnostic marker in earlier stages of PD. A significant relationship was found between TB and motor asymmetry in HY I patients. According to our findings, bilirubin mainly exhibits its protective effects in HY I population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability Statement
The data used in this research was obtained from PPMI and is available with permission to all researchers.
References
Boonstra TA, van Vugt JPP, van der Kooij H, Bloem BR (2014) Balance asymmetry in Parkinson’s disease and its contribution to freezing of gait. PLoS ONE 9:e102493. https://doi.org/10.1371/JOURNAL.PONE.0102493
Cotogni M, Sacchi L, Sadikov A, Georgiev D (2021) Asymmetry at disease onset is not a predictor of Parkinson’s disease progression. Journal of Parkinson’s Disease 11:1689–1694. https://doi.org/10.3233/JPD-202525
Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86:109–127. https://doi.org/10.1093/BMB/LDN013
Djaldetti R, Ziv I, Melamed E (2006) The mystery of motor asymmetry in Parkinson’s disease. The Lancet Neurol 5:796–802. https://doi.org/10.1016/S1474-4422(06)70549-X
Djoussé L, Levy D, Cupples LA et al (2001) Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 87:1196–1200. https://doi.org/10.1016/S0002-9149(01)01494-1
Doré S, Takahashi M, Ferris CD et al (1999) Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc Natl Acad Sci U S A 96:2445–2450. https://doi.org/10.1073/PNAS.96.5.2445
Elbaz A, Bower JH, Peterson BJ et al (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96. https://doi.org/10.1001/ARCHNEUR.60.1.91
Elstner M, Müller SK, Leidolt L et al (2011) Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol Brain 4:1–10. https://doi.org/10.1186/1756-6606-4-43
Espay AJ, Li JY, Johnston L et al (2005) Mirror movements in parkinsonism: evaluation of a new clinical sign. J Neurol Neurosurg Psychiatry 76:1355–1359. https://doi.org/10.1136/JNNP.2005.062950
Gan-Or Z, Giladi N, Rozovski U et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283. https://doi.org/10.1212/01.WNL.0000304039.11891.29
Grajić M, Stanković I, Radovanović S, Kostić V (2015) Gait in drug naïve patients with de novo Parkinson’s disease – altered but symmetric. Neurol Res 37:712–716. https://doi.org/10.1179/1743132815Y.0000000043
Hausdorff JM (2009) Gait dynamics in Parkinson’s disease: common and distinct behavior among stride length, gait variability, and fractal-like scaling. Chaos. https://doi.org/10.1063/1.3147408
Heo HY, Park JM, Kim CH et al (2010) LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res 316:649–656. https://doi.org/10.1016/J.YEXCR.2009.09.014
Huang X, Mahoney JM, Lewis MM et al (2012) Both coordination and symmetry of arm swing are reduced in Parkinson’s disease. Gait Posture 35:373–377. https://doi.org/10.1016/J.GAITPOST.2011.10.180
Hunt SC, Kronenberg F, Eckfeldt JH et al (2001) Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 154:747–754. https://doi.org/10.1016/S0021-9150(00)00420-2
Jin JN, Liu X, Li MJ et al (2020) Association between serum bilirubin concentration and Parkinson’s disease: a meta-analysis. Chin Med J (engl) 134:655–661. https://doi.org/10.1097/CM9.0000000000001300
Lee CS, Schulzer M, Mak E et al (1995) Patterns of asymmetry do not change over the course of idiopathic Parkinsonism. Neurology 45:435–439. https://doi.org/10.1212/WNL.45.3.435
Lee SH, Park SM, Yeo SS et al (2022) Parkinson’s disease subtyping using clinical features and biomarkers: literature review and preliminary study of subtype clustering. Diagnostics 12(112):112. https://doi.org/10.3390/DIAGNOSTICS12010112
Lewek MD, Poole R, Johnson J et al (2010) Arm swing magnitude and asymmetry during gait in the early stages of Parkinson’s disease. Gait Posture 31:256–260. https://doi.org/10.1016/J.GAITPOST.2009.10.013
Llesuy SF, Tomaro ML (1994) Heme oxygenase and oxidative stress. Evidence of involvement of bilirubin as physiological protector against oxidative damage. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1223:9–14. https://doi.org/10.1016/0167-4889(94)90067-1
Macías-García D, Méndez-Del Barrio C, Jesús S et al (2019) Increased bilirubin levels in Parkinson’s disease. Parkinsonism Relat Disord 63:213–216. https://doi.org/10.1016/J.PARKRELDIS.2019.01.012
Marinus J, van Hilten JJ (2015) The significance of motor (a)symmetry in Parkinson’s disease. Mov Disord 30:379–385. https://doi.org/10.1002/MDS.26107
McCarty MF (2013) Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues – a rationale for the versatile health protection associated with elevated plasma bilirubin. Med Hypotheses 81:607–610. https://doi.org/10.1016/J.MEHY.2013.07.013
Miller-Patterson C, Buesa R, McLaughlin N et al (2018) Motor asymmetry over time in Parkinson’s disease. J Neurol Sci 393:14–17. https://doi.org/10.1016/J.JNS.2018.08.001
Mirelman A, Bonato P, Camicioli R et al (2019) Gait impairments in Parkinson’s disease. The Lancet Neurol 18:697–708. https://doi.org/10.1016/S1474-4422(19)30044-4
Moccia M, Picillo M, Erro R et al (2015) Increased bilirubin levels in de novo Parkinson’s disease. Eur J Neurol 22:954–959. https://doi.org/10.1111/ENE.12688
Nguyen HN, Byers B, Cord B et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8:267–280. https://doi.org/10.1016/J.STEM.2011.01.013
Orr-Urtreger A, Shifrin C, Rozovski U et al (2007) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease. Neurology 69:1595–1602. https://doi.org/10.1212/01.WNL.0000277637.33328.D8
Ortelli P, Ferrazzoli D, Zarucchi M et al (2018) Asymmetric dopaminergic degeneration and attentional resources in Parkinson’s disease. Front Neurosci 12:972. https://doi.org/10.3389/FNINS.2018.00972
Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:1 3:1–21. https://doi.org/10.1038/nrdp.2017.13
Qin X ling, Zhang Q Shan, Sun L et al (2014) Lower serum bilirubin and uric acid concentrations in patients with Parkinson’s disease in China. Cell Biochem Biophys 72:1 72:49–56. https://doi.org/10.1007/S12013-014-0402-X
Reiter RJ (1995) Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 9:526–533. https://doi.org/10.1096/FASEBJ.9.7.7737461
Roggendorf J, Chen S, Baudrexel S et al (2012) Arm swing asymmetry in Parkinson’s disease measured with ultrasound based motion analysis during treadmill gait. Gait Posture 35:116–120. https://doi.org/10.1016/J.GAITPOST.2011.08.020
San Luciano M, Wang C, Ortega RA et al (2017) Sex differences in LRRK2 G2019S and idiopathic Parkinson’s disease. Ann Clin Transl Neurol 4:801–810. https://doi.org/10.1002/ACN3.489
Schipper HM, Song W, Zukor H et al (2009) Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 110:469–485. https://doi.org/10.1111/J.1471-4159.2009.06160.X
Scigliano G, Girotti F, Soliveri P et al (1997) Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis? Ital J Neurol Sci 18:2 18:69–72. https://doi.org/10.1007/BF01999565
Skorvanek M, Martinez-Martin P, Kovacs N et al (2017) Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration. Mov Disord Clin Pract 4:536–544. https://doi.org/10.1002/MDC3.12476
Sterling NW, Cusumano JP, Shaham N et al (2015) Dopaminergic modulation of arm swing during gait among Parkinson’s disease patients. J of Parkinsons Dis 5:141–150. https://doi.org/10.3233/JPD-140447
Stocker R, Yamamoto Y, McDonagh AF et al (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046. https://doi.org/10.1126/SCIENCE.3029864
Toth C, Rajput M, Rajput AH (2004) Anomalies of asymmetry of clinical signs in parkinsonism. Mov Disord 19:151–157. https://doi.org/10.1002/MDS.10685
Vila MH, Pérez R, Mollinedo I, Cancela JM (2021) Analysis of gait for disease stage in patients with Parkinson’s disease. Int J Environ Health Res 18(18):720. https://doi.org/10.3390/IJERPH18020720
Wang X, Yan MH, Fujioka H et al (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21:1931–1944. https://doi.org/10.1093/HMG/DDS003
West AB, Moore DJ, Biskup S et al (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842–16847. https://doi.org/10.1073/PNAS.0507360102
Wu G, Jiang Z, Pu Y et al (2022) Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients. BMC Neurol 22:1–9. https://doi.org/10.1186/S12883-021-02544-7
Acknowledgements
PPMI—a public–private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners. Full names of all of the PPMI funding partners can be found at www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors.
Author information
Authors and Affiliations
Contributions
DK contributed to conceptualization, data curation, drafting manuscript, and development of methodology. HH contributed to conceptualization, data curation, and drafting manuscript. ASC revised and edited the manuscript. All authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Statement of Ethics
This study was conducted using PPMI data. The PPMI study is ethically approved and conducted in accordance with the Declaration of Helsinki, 1964.
Ethical Review Board
The ethical approval of PPMI is available at ClinicalTrials.gov with Identifier: NCT01141023.
Informed Consent
Written informed consent was obtained from the participants.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kazemi, D., Hajishah, H. & Chadeganipour, A.S. Association of Total Bilirubin with Motor Signs in Early Parkinson’s Disease in LRRK2 Variant Carriers. J Mol Neurosci 72, 2338–2344 (2022). https://doi.org/10.1007/s12031-022-02067-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-022-02067-x